Bayer Shares Rise as Pharma Recovery Lifts Full-Year Earnings Outlook
Bayer raised its 2026 EBITDA guidance on a pharma rebound, and its shares gained 5.6% in early European trading.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to Dow Jones Newswires, Bayer shares climbed 5.6% in European morning trading on Tuesday. The German group raised its full-year underlying EBITDA forecast to 9.8–10.3 billion euros from 9.6–10.1 billion. The upgrade follows stronger demand for the prostate-cancer drug Nubeqa and the kidney and heart medicine Kerendia in its pharma unit.
Third-quarter sales reached 10.05 billion euros, up 4.1% year on year and above the 9.93 billion euro consensus cited by Vara Research. The net loss narrowed to 672 million euros from 963 million, although impairments and litigation costs weighed on results. Excluding exceptional items, EBITDA rose 6.9% to 1.615 billion euros, beating forecasts.
Bayer also now expects year-end net debt of 28–29 billion euros, down from its earlier 29–30 billion euro target.
why it matters
Bayer is one of Europe's largest pharmaceutical and agricultural companies, so its results shape sentiment across the German and European healthcare sector. The raised outlook suggests the company is managing patent losses on Xarelto and Eylea and its U.S. Roundup litigation better than investors had feared.
market impact
Bayer shares and European pharma: the raised outlook supports the company's stock
- Bayer shares pressure up — higher EBITDA guidance and strong pharma results
tags
instruments
sources
- Bayer Shares Jump After Pharma Recovery Prompts Outlook Raise — Dow Jones Newswires, 3 November 2026 at 09:06 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗